周一，Hims & Hers Health Inc. 发表声明： 诺和诺德 的诉讼是对数百万依赖复方药获得个性化治疗的美国民众公然的攻击，大型制药企业再次将美国司法体系武器化以限制消费者选择。
声明称，Hims & Hers Health长期为数百万美国人提供安全获取个性化医疗服务的渠道，将继续奋战以保障选择权、可负担性及可及性。
诺和诺德当天早些时候宣布，已就Hims & Hers Health在美国市场销售的复方司美格鲁肽产品侵犯专利提起诉讼。
截至发稿，Hims & Hers Health的盘前跌幅扩大至超22%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
